Jane Street’s Loncar China BioPharma ETF CHNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-19,335
| Closed | -$276K | – | 10096 |
|
|
2023
Q3 | $276K | Buy |
19,335
+7,357
| +61% | +$113K | ﹤0.01% | 7182 |
|
|
2023
Q2 | $194K | Buy |
+11,978
| New | +$208K | ﹤0.01% | 7695 |
|
|
2023
Q1 | – | Sell |
-29,839
| Closed | -$560K | – | 10295 |
|
|
2022
Q4 | $560K | Buy |
29,839
+2,928
| +11% | +$49K | ﹤0.01% | 5936 |
|
|
2022
Q3 | $386K | Buy |
+26,911
| New | +$478K | ﹤0.01% | 7164 |
|
|
2022
Q1 | – | Sell |
-61,266
| Closed | -$1.64M | – | 11283 |
|
|
2021
Q4 | $1.64M | Buy |
61,266
+24,430
| +66% | +$802K | ﹤0.01% | 4877 |
|
|
2021
Q3 | $1.37M | Buy |
+36,836
| New | +$1.5M | ﹤0.01% | 5277 |
|
|
2021
Q2 | – | Sell |
-20,956
| Closed | -$773K | – | 10631 |
|
|
2021
Q1 | $773K | Sell |
20,956
-20,410
| -49% | -$761K | ﹤0.01% | 5967 |
|
|
2020
Q4 | $1.35M | Sell |
41,366
-7,275
| -15% | -$223K | ﹤0.01% | 4186 |
|
|
2020
Q3 | $1.49M | Buy |
48,641
+20,148
| +71% | +$637K | ﹤0.01% | 3465 |
|
|
2020
Q2 | $876K | Sell |
28,493
-28,891
| -50% | -$767K | ﹤0.01% | 4257 |
|
|
2020
Q1 | $1.3M | Buy |
+57,384
| New | +$1.42M | ﹤0.01% | 2496 |
|
|
2019
Q3 | – | Sell |
-12,166
| Closed | -$270K | – | 5946 |
|
|
2019
Q2 | $270K | Buy |
+12,166
| New | +$279K | ﹤0.01% | 4340 |
|
Jane Street's CHNA Position: Q4 2023 in Review
Jane Street sold out of Loncar China BioPharma ETF (CHNA) in Q4 2023, closing a stake of 19,335 shares — an estimated $276K sold.
Jane Street first reported a position in CHNA in Q2 2019 and held it in 12 quarters. The position peaked at $1.64M in Q4 2021. 0 funds tracked by Wall St. Rank hold CHNA as of Q4 2023.
- Jane Street reported no remaining Loncar China BioPharma ETF position as of Q4 2023 after selling out during the quarter.
- Jane Street sold 19,335 Loncar China BioPharma ETF shares in Q4 2023, an estimated $276K.
- Jane Street first reported a position in Loncar China BioPharma ETF in Q2 2019 and held it in 12 quarters.
- Jane Street's Loncar China BioPharma ETF position peaked at $1.64M in Q4 2021.
- 0 funds tracked by Wall St. Rank held Loncar China BioPharma ETF as of Q4 2023.
Based on Jane Street's 13F filing for Q4 2023, filed 15 Feb 2024.